New human reproductive hormone could lead to novel contraceptives

December 22, 2009

Nearly 10 years after the discovery that birds make a hormone that suppresses reproduction, University of California, Berkeley, neuroscientists have established that humans make it too, opening the door to development of a new class of contraceptive and possible treatments for cancer or other diseases.

The hormone, gonadotropin inhibitory hormone (GnIH), has the opposite effect from gonadotropin releasing hormone, a key reproductive hormone. While GnRH triggers a cascade of hormones that prime the body for sex and procreation, GnIH puts a brake on the cascade.

"Identifying the inhibitory hormone in humans forces us to revise our understanding of the control mechanism of human reproduction," said first author Takayoshi Ubuka, a post-doctoral fellow in the UC Berkeley Department of Integrative Biology and in the Helen Wills Neuroscience Institute. "We hope this will stimulate clinical studies on people with precocious puberty or in the area of contraception."

Because reproductive hormones often promote the growth of cancer cells, GnIH might also work as an anti-cancer agent.

"Frequently, treatment of hormone-responsive cancers involves GnRH antagonists or very, very high doses of GnRH, which cause side effects," said George Bentley, UC Berkeley assistant professor of integrative biology. "Maybe we can use something that inhibits reproduction at physiological levels, so that we can bypass some of these side effects."

Ubuka, Bentley and their colleagues at UC Berkeley and in Japan and the United Kingdom report their findings in the Dec. 22 online issue of the public access journal PLoS ONE.

GnIH was discovered in 2000 in quail and has been studied in other birds, in mice and in sheep, but its role in humans has been hard to pin down. While the human genome contains the gene for GnIH, it was unclear if, when and where the protein hormone is produced, and whether it affects reproduction.

The UC Berkeley researchers extracted two versions of the hormone from human brains (five human hypothalami). They found that the human GnIH gene produces a precursor protein that is cut up to form 12 and 8 amino acid mature peptides.

"One of the peptides in sheep has the same amino acid sequence as the human peptide, so we can study its activity in sheep to learn about its activity in humans," Bentley said. "It's likely that the function of GnIH is evolutionarily conserved."

They also showed that the hormones are present in a region of the brain, the hypothalamus, that controls reproduction. In addition, GnIH affects nerve cells that secrete GnRH, which is in line with previous findings that GnIH down-regulates GnRH.

Finally, they found that the hypothalamus and pituitary - two key parts of the reproductive axis in the brain have receptors for the hormones.

All the previous work on birds, rodents, sheep and even macaque monkeys - much of it performed by Bentley's group and by a group led by the discoverer of GnIH, Kazuyoshi Tsutsui at Waseda University in Tokyo hint at a wealth of interactions between GnIH and the reproductive system. Only recently, the human hormone was shown to inhibit the release of gonadotropin in sheep.

"GnIH pushes the pause button on reproduction, but in a variety of ways," Bentley said. "It can act on GnRH neurons in the hypothalamus, inhibiting GnRH release; it can act directly on pituitary; or it can influence the gonads directly. The overall effect is to inhibit reproduction, but at different levels of the reproductive axis."

GnIH might even be a key regulator of puberty, Ubuka said.

Bentley and Ubuka continue to investigate how GnIH acts in humans as well as in starlings and zebra finches.
-end-
Other coauthors of the PLoS ONE paper are Kevin Morgan, Adam J. Pawson and Robert P. Millar of the Centre for Reproductive Biology at The Queen's Medical Research Institute in Edinburgh, Scotland; Kazuyoshi Tsutsui, Tomohiro Osugi and Vishwajit S. Chowdhury of Waseda University; and Hiroyuki Minakata of the Suntory Institute for Bioorganic Research in Osaka, Japan.

The work was funded by the Hellmann Family Foundation, the National Science Foundation and a UC Berkeley COR Junior Faculty Research Grant.

University of California - Berkeley

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.